CureVac has filed for an initial public offering in the US, 20 years after being spun out of Eberhard Karls University of Tübingen.
CureVac, a Germany-based messenger RNA (mRNA) drug developer spun out of Eberhard Karls University of Tübingen, on Friday filed for an initial public offering on the Nasdaq Global Market with a placeholder target of $100m.
The company has not yet set any terms for the proposed offering.
Founded in 2000, CureVac is working on treatments that exploit mRNA to create immunotherapies aimed at diseases including cancer, as well as vaccines for infectious diseases such as rabies and…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
